论文部分内容阅读
目的:观察口服谷氨酰胺(Gln)对局部晚期非小细胞肺癌(LANSCLC)行同步放化疗病人放射性损伤、营养状况和生存率的影响。方法:对112例诊断为LANSCLC行同步放化疗的病人资料进行回顾性分析。其中Gln组60例病人在治疗中口服Gln,对照组52例未使用Gln。观察病人在治疗期间和治疗后1个月内,放射性食管炎、上消化道症状的发生情况,治疗前后的体重变化,并随访病人的生存情况,比较3年后两组病人的生存率。结果:两组病人急性放射性食管炎(ARIE)的发生率和生存率无显著性差异(P>0.05)。但Gln组ARIE进展速度明显减慢,导致临床治疗中断的时间明显缩短,放化疗期间的体重下降也明显减少(P<0.05)。结论:Gln有助于缓解ARIE的严重程度和放化疗导致的体重下降,可联合放射性保护药物用于临床治疗。
OBJECTIVE: To observe the effect of oral glutamine (Gln) on radioactive injury, nutritional status and survival rate in patients with locally advanced non-small cell lung cancer (LANSCLC) undergoing concurrent chemoradiotherapy. Methods: A retrospective analysis was performed on 112 patients diagnosed as concurrent chemoradiotherapy with LANSCLC. Gln group of 60 patients in the treatment of oral Gln, 52 cases of the control group did not use Gln. Radiation esophagitis and upper gastrointestinal symptoms were observed during the treatment and within 1 month after treatment. The changes of body weight before and after treatment were observed. The survival of patients were followed up. The survival rates of the two groups were compared after 3 years. Results: There was no significant difference in the incidence and survival rate of acute esophagitis esophagitis (ARIE) between the two groups (P> 0.05). However, the progress of ARIE in Gln group was significantly slowed down, leading to significantly shorter interruption of clinical treatment and weight loss during radiotherapy and chemotherapy (P <0.05). Conclusion: Gln can help to alleviate the severity of ARIE and the weight loss caused by radiotherapy and chemotherapy, and can be used in combination with radioprotective drugs for clinical treatment.